# US 2008/0167380 A1 · Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0167380 A1
- Document ID: US20080167380A1
- Status: Published application
- Kind: A1
- Application number: 11/910,673
- Filed: 2006-03-10
- Published: 2008-07-10
- Earliest claimed: 2005-04-04
- Assignees: Merck Patent GmbH
- Inventors: Rolf Gericke; Dieter Dorsch; Werner Mederski; Markus Klein; Norbert Beier; Florian Lang
- Web page: https://patentgrep.com/patent/US20080167380A1

## CPC

- C07C 323/62: having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/12: for cataracts
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 243/38: with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
- C07C 255/57: containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Novel acyl hydrazides of the formula (I), in which R1-R9 have the meanings indicated in claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in fibroses and inflammatory processes of any type.

## Claims

### Claim 1

Compounds of the formula I
in which
R1R2, R3, R4, R5,
R6, R7, R8, R9 each, independently of one another, denote H, A, OSO2A, Hal, NO2, OR10, N(R10)2, CN, —[C(R10)2]nCOOR10, O—[C(R10)2]oCOOR10, SO3H, —[C(R10)2]nAr, —CO—Ar, O—[C(R10)2]nAr, —[C(R10)2]nHet, —[C(R10)2]nC≡CH, O—[C(R10)2]nC≡CH, —[C(R10)2]nCON(R10)2, —[C(R10)2]nCONR10N(R10)2, O—[C(R10)2]nCON(R10)2, O—[C(R10)2]oCONR10N(R10)2, NR10COA, NR10CON(R10)2, NR10SO2A, N(SO2A)2, COR10, S(O)mAr, SO2NR10 or S(O)mA,
R1 and R2, R2 and R3,
R3 and R4 or R4 and R5 together also denote CH═CH—CH═CH,
A denotes unbranched or branched alkyl having 1-6 C atoms, in which 1-7H atoms may be replaced by F, or cyclic alkyl having 3-7 C atoms,
Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR10, N(R10)2, NO2, CN, phenyl, CON(R10)2, NR10COA, NR10CON(R10)2, NR10SO2A, COR10, SO2N(R10)2, S(O)mA, —[C(R10)2]o—COOR10 and/or —O[C(R10)2]o—COOR10,
Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be mono-, di- or trisubstituted by Hal, A, OR10, N(R10)2, NO2, CN, COOR10, CON(R10)2, NR10COA, NR10SO2A, COR10, SO2NR10, S(O)mA, ═S, ═NR10 and/or ═O (carbonyl oxygen),
R10 denotes H or A,
Hal denotes F, Cl, Br or I,
m denotes 0, 1 or 2,
n denotes 0, 1, 2 or 3,
0 denotes 1, 2 or 3,
and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 2 (depends on 1)

Compounds according to claim 1 in which
R1 denotes H, A, Hal, NO2, OR10, —[C(R10)2]nAr or O—[C(R10)2]nAr, and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 3 (depends on 1)

Compounds according to claim 1 in which
R2 denotes H, A, Hal, CN, NO2, OR10, —[C(R10)2]nAr or O—[C(R10)2]nAr,
and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 4 (depends on 1)

Compounds according to claim 1 in which
R3 denotes H, A, Hal, NO2, OR10, —[C(R10)2]nAr, O—[C(R10)2]nAr, —[C(R10)2]nCOOR10 or S(O)mA,
and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 5 (depends on 1)

Compounds according to claim 1 in which
R4 denotes H, A, Hal, CONH2, CN, NO2 or OR10,
and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 6 (depends on 1)

Compounds according to claim 1 in which
R5 denotes H, A, Hal, OR10, —[C(R10)2]nAr or O—[C(R10)2]nAr,
and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 7 (depends on 1)

Compounds according to claim 1 in which
R6 denotes H or A,
and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 8 (depends on 1)

Compounds according to claim 1 in which
R7 denotes H, A or OR10,
and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 9 (depends on 1)

Compounds according to claim 1 in which
R8 denotes H, A or OR10,
and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 10 (depends on 1)

Compounds according to claim 1 in which
R9 denotes H or A,
and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 11 (depends on 1)

Compounds according to claim 1 in which
Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal and/or A,
and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 12 (depends on 1)

Compounds according to claim 1 in which
Het denotes a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, OH and/or OA,
and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 13 (depends on 1)

Compounds according to claim 1 in which
Het denotes a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono- or disubstituted by A,
and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 14 (depends on 1)

Compounds according to claim 1 in which
Het denotes furyl, thienyl, pyrrolyl, imidazolyl, pyridyl, pyrimidinyl, pyrazolyl, thiazolyl, indolyl, pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl, each of which is unsubstituted or mono-, di- or trisubstituted by A, Hal, OH and/or OA,
and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 15 (depends on 1)

Compounds according to claim 1 in which
R1 denotes H, A, Hal, NO2, OR10, —[C(R10)2]nAr or O—[C(R10)2]nAr,
R2 denotes H, A, Hal, CN, N(R10)2, NO2, OR10, —[C(R10)2]nAr or
O—[C(R10)2]nAr,
R3 denotes H, A, Hal, NO2, OR10, —[C(R10)2]nAr, O—[C(R10)2]nAr, —[C(R10)2]nCOOR10 or S(O)mA,
R4 denotes H, A, Hal, CONH2, CN, NO2 or OR10,
R5 denotes H, A, Hal, OR10, —[C(R10)2]nAr or O—[C(R10)2]nAr,
R6 denotes H,
R7 denotes H or OR10,
R8 denotes H or OR10,
R9 denotes H,
R1 and R2, R2 and R3,
R3 and R4 or R4 and R5 together also denote CH═CH—CH═CH,
A denotes unbranched or branched alkyl having 1-6 C atoms, in which 1-7H atoms may be replaced by F,
Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal and/or A,
R10 denotes H or A,
Hal denotes F, Cl, Br or I,
m denotes 0, 1 or 2,
n denotes 0, 1, 2 or 3,
and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 16 (depends on 1)

Compounds according to claim 1 in which
R1 denotes OH, A or Hal,
R2 denotes H, A or Hal,
R3 denotes OH,
R4 denotes H, A or Hal,
R5 denotes H or OH,
R6 denotes H,
R7 denotes H,
R8 denotes H.
R9 denotes H,
R1 and R2, R2 and R3,
R3 and R4 or R4 and R5 together also denote CH═CH—CH═CH,
A denotes unbranched or branched alkyl having 1-6 C atoms, in which 1-7H atoms may be replaced by F,
Hal denotes F, Cl, Br or I,
and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 17 (depends on 1)

Compounds according to claim 1 selected from the group
No.
Structural formula
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 18 (depends on 1)

Process for the preparation of compounds of the formula I according to claim 1 and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, characterised in that
a) a compound of the formula II
in which
R6, R7, R8 and R9 have the meanings indicated in claim 1,
is reacted with a compound of the formula III
in which
L denotes Cl, Br, I or a free or reactively functionally modified OH group and
R1, R2, R3, R4 and R5 have the meanings indicated in claim 1, or
b) a compound of the formula IV
in which
R1, R2, R3, R4 and R5 have the meanings indicated in claim 1,
is reacted with a compound of the formula V
in which
L denotes Cl, Br, I or a free or reactively functionally modified OH group and
R6, R7, R8 and R9 have the meanings indicated in claim 1, or
c) a radical R1, R2, R3, R4, R5, R6, R7, R8 and/or R9 in a compound of the formula I is converted into another radical R1, R2, R3, R4, R5, R6, R7, R8 and/or R9
by cleaving an ether by hydrolysis or hydrogenolysis,
and/or a base or acid of the formula I is converted into one of its salts.

### Claim 19 (depends on 1)

Medicaments comprising at least one compound according to claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.

### Claim 20 (depends on 1)

Use of compounds according to claim 1, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment and/or prophylaxis of diseases in which the inhibition, regulation and/or modulation of kinase signal transduction plays a role.

### Claim 21 (depends on 20)

Use according to claim 20, where the kinase is SGK.

### Claim 22 (depends on 1)

Use of compounds according to claim 1, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of diseases which are influenced by inhibition of SGKs by the compounds according to claim 1.

### Claim 23 (depends on 22)

Use according to claim 22 for the treatment or prevention of diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in fibroses and inflammatory processes of any type, cancer, tumour cells, tumour metastases, coagulopathies, neuronal excitability, glaucoma, cataract, bacterial infections and in antiinfection therapy, for increasing learning ability and attention, and for the treatment and prophylaxis of cell ageing and stress, and for the treatment of tinnitus.

### Claim 24 (depends on 23)

Use according to claim 23, where diabetes is diabetes mellitus, diabetic nephropathy, diabetic neuropathy, diabetic angiopathy and microangiopathy.

### Claim 25 (depends on 23)

Use according to claim 23, where cardiovascular diseases are cardiac fibroses after myocardial infarction, cardiac hypertrophy, cardiac insufficiency and arteriosclerosis.

### Claim 26 (depends on 23)

Use according to claim 23, where renal diseases are glomerulosclerosis, nephrosclerosis, nephritis, nephropathy and electrolyte excretion disorder.

### Claim 27 (depends on 23)

Use according to claim 23, where fibroses and inflammatory processes are liver cirrhosis, pulmonary fibrosis, fibrosing pancreatitis, rheumatism and arthroses, Crohn's disease, chronic bronchitis, radiation fibrosis, sclerormatitis, cystic fibrosis, scarring and Alzheimer's disease.

### Claim 28 (depends on 1)

Medicaments comprising at least one compound according to claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

### Claim 29 (depends on 1)

Set (kit) consisting of separate packs of
(a) an effective amount of a compound according to claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and
(b) an effective amount of a further medicament active ingredient.

### Claim 30 (depends on 1)

A method for the treatment and/or prophylaxis of diseases in which the inhibition, regulation and/or modulation of kinase signal transduction plays a role comprising administering a compound of claim 1.
